Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Innovative Pipeline | Tango Therapeutics' PRMT5 inhibitor trials for pancreatic and lung cancers could revolutionize treatment, with expansion data expected in late 2025 |
Financial Outlook | Despite projected losses, Tango extends cash runway to Q1 2027, demonstrating efficient capital allocation and maintaining a healthy current ratio of 6.26 |
Market Positioning | Explore Tango's unique position in targeted cancer therapies, with recent 53% price return and analyst price target of $13, despite being 61% below 52-week high |
Growth Potential | Delve into Tango's opportunities in precision oncology, including expansion into multiple cancer indications and potential partnerships with pharmaceutical giants |
Metrics to compare | TNGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTNGXPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.1x | −1.1x | −0.5x | |
PEG Ratio | 0.26 | −0.06 | 0.00 | |
Price/Book | 5.5x | 2.2x | 2.6x | |
Price / LTM Sales | 30.7x | 9.4x | 3.3x | |
Upside (Analyst Target) | 53.8% | 312.7% | 43.5% | |
Fair Value Upside | Unlock | 19.2% | 6.9% | Unlock |